Irritable Bowel Syndrome (IBS) Clinical Trial Pipeline Highlights 2019 – Global Forecast to 2024 by Clinical Trial Stages, Drug Mechanism Classes, Company – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Irritable Bowel Syndrome Clinical Trial Pipeline Highlights – 2019”
report has been added to ResearchAndMarkets.com’s
offering.

Irritable Bowel Syndrome Pipeline Highlights – 2019 provides the most
up-to-date information on key pipeline products in the global Irritable
Bowel Syndrome market. It covers emerging therapies for Irritable Bowel
Syndrome in active clinical development stages including early and late
stage clinical trials. The pipeline data presented in this report helps
executives for tracking competition, identifying partners, evaluating
opportunities, formulating business development strategies, and
executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Irritable Bowel Syndrome pipeline products by
clinical trial stages including both early and late stage development –
phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical
trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Irritable Bowel Syndrome pipeline products by their
dominant mechanism of action/drug class. This helps executives
categorize products based on their drug class and also assess the
strengths and weaknesses of compounds.

Company:

The report provides Irritable Bowel Syndrome pipeline products by the
company.

Short-term Launch Highlights:

Find out which Irritable Bowel Syndrome pipeline products will be
launched in the US and Ex-US till 2024.

Key Topics Covered:

1. Irritable Bowel Syndrome Pipeline by Stages

2. Irritable Bowel Syndrome Phase 3 Clinical Trial Insights

3. Irritable Bowel Syndrome Phase 2 Clinical Trial Insights

4. Irritable Bowel Syndrome Phase 1 Clinical Trial Insights

5. Irritable Bowel Syndrome Preclinical Research Insights

6. Irritable Bowel Syndrome Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/8ub2oz

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Clinical
Trials, Gastrointestinal
Drugs